

Microarray genotyping + Beagle 5.5 imputation against 1000 Genomes Phase 3. Polygenic scores from PGS Catalog. PGx via CPIC/DPWG guidelines.

PHARMACOGENOMICS & DRUG GUIDANCE

Gene	Diplotype	Phenotype	Clinical Guidance
CYP2B6	*1/*9	Intermediate Metabolizer	Altered metabolism of efavirenz, bupropion, methadone.
CYP2C9	*1/*2	Intermediate Metabolizer	Reduced warfarin/phenytoin metabolism. Lower starting doses recommended.
CYP3A5	*1/*3	Intermediate Metabolizer	Altered tacrolimus metabolism. May need dose adjustment.
NAT2	*1/*5	Intermediate Metabolizer	Slow acetylator. Risk of isoniazid toxicity; consider dose reduction.
SLCO1B1	*1/*5	Decreased Function	Reduced simvastatin transport. Consider rosuvastatin or pravastatin.
ABCG2	rs2231142 reference (G)/r	Normal Function	Standard rosuvastatin transport.

Microarray-based. Confirm with clinical PGx panel before prescribing changes. Results do not replace clinical judgement, targeted sequencing, or comprehensive pharmacogenomic testing.